topical vasoconstrictor

Phase III Results of Topical Brimonidine for Rosacea Released

Topical brimonidine tartrate gel 0.5% (Galderma, www.galderma.com) is significantly more efficacious than vehicle in the treatment of rosacea-related erythema. Joseph Fowler, MD, et al, have published the findings of two phase III pivotal trials on brimonidine in the Journal of Drugs in Dermatology(June 2013). The multicenter, randomized, double-blind, parallel-group studies included 260 subjects and 293 subjects, respectively, and were carried out between May 2011 and November 2011.

Syndicate content